NEW YORK – Roche said this week that the US Food and Drug Administration has granted the company's Elecsys Galad score breakthrough device designation. The algorithmic score combines a patient gender’s and age, and the results of Roche’s Elecsys test for biomarkers AFP, AFP-L3, and PIVKA-II to aid in the diagnosis of early-stage hepatocellular carcinoma.